FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
New data shed light on the best strategies for managing patients who develop interstitial lung disease (ILD) while being treated with trastuzumab deruxtecan. City of…
The American Journal of Managed Care News section is a comprehensive resource for clinical news and expert insights. Read more at AJMC.
Five-Year Outcomes With First-Line Nivolumab + Ipilimumab With Chemotherapy vs Chemotherapy in Patients With Metastatic NSCLC in CheckMate 9LA Please see US Full Prescribing Information…
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
Adolescent and young adult (AYA) patients with hematological diseases have unique needs that require a multidisciplinary strategy to ensure their mental and sexual well-being during…
The late-breaking abstracts presented on the last day of the 2025 European Hematology Association (EHA) Congress show “what a vibrant clinical specialty we’re in,” according…
Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation…
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
